Autistic children and adults fall asleep, stay asleep, and sleep through the night at meaningfully lower rates than the general population — a systematic update of the research puts sleep problems across included samples at 37–93% of autistic children (mean around 71%), with sleep-onset insomnia (trouble falling asleep) the single most common issue, at roughly 65% on average.1 Melatonin is the best-studied supplement for this specific symptom, with genuine double-blind, placebo-controlled trial evidence behind it — most of it in autistic children, using a prescription-strength formulation.4 None of that evidence means melatonin treats autism itself — autism isn't a disease, and no supplement changes it. It means melatonin has real support for helping with one common, exhausting, co-occurring symptom: sleep difficulty. It's also worth saying plainly up front: the strongest trial evidence is pediatric, and Proco's melatonin-containing products are formulated for adults, not children. If you're a parent or caregiver considering melatonin for an autistic child, that's a conversation for a pediatrician, not an adult supplement label.
How common are sleep difficulties in autistic people?
Very common — more common than almost any other co-occurring feature of autism. A narrative review and systematic update in Current Sleep Medicine Reports found that sleep problems are reported for up to 80% of autistic individuals, with estimates across the included samples ranging from 37% to 93% (mean 71.4%, SD 15.9).1 That spread is wide for a reason: studies differ in how they define and measure sleep problems, and in who they recruit. Sleep-onset insomnia was on average the most common single issue, at around 65% — though with a range from 20% to 97% across studies, which is a reminder that any single headline percentage in this literature is doing a lot of averaging.1
This isn't only a childhood pattern, but the adult evidence base is much smaller than most coverage implies. A systematic review and meta-analysis in Sleep Medicine pooled 14 publications covering 8 datasets — just 194 autistic adults and 277 controls — and found impaired sleep on 6 of 11 subjective parameters and 10 of 17 objective ones, including lower sleep efficiency (SMD −0.87), longer polysomnography-measured sleep onset latency (SMD 0.86) and more wake after sleep onset on actigraphy (SMD 0.57).2 Those are substantial effect sizes; the sample behind them is small. Both things are true, and we'd rather say so than round a 194-person dataset up to "nearly 80% of autistic adults," which is what an earlier version of this article did on the strength of a consumer website.
Autism itself is also more common than older estimates suggested: the CDC's most recent surveillance data (2022 surveillance year, ADDM Network) puts prevalence among 8-year-olds at about 1 in 31 children, or 3.2% — 32.2 per 1,000.3 Combined with sleep-difficulty rates this high, that means a genuinely large number of people are dealing with chronic, disruptive sleep problems that standard sleep-hygiene advice often doesn't fully resolve.
What the melatonin trials actually show
Melatonin is, by a wide margin, the most-studied supplement for sleep problems in autism. A 2011 systematic review and meta-analysis identified 35 studies and pooled five randomized, double-blind, placebo-controlled trials. It found significant improvements with large effect sizes in sleep duration and sleep onset latency — but not in night-time awakenings, which did not reach significance. Side effects reported across the studies were minimal to none.5 That null on night waking is worth carrying forward: it suggests melatonin is doing something to sleep timing and onset rather than acting as a general sedative that keeps you under.
The strongest single piece of evidence is a randomized, double-blind, placebo-controlled trial of a pediatric prolonged-release melatonin formulation (PedPRM), led by Paul Gringras and colleagues.4 A total of 125 children and adolescents aged 2 to 17.5 — 96.8% with autism spectrum disorder, 3.2% with Smith-Magenis syndrome — whose sleep had already failed to improve on behavioural intervention alone were randomised to PedPRM (2mg escalating to 5mg) or placebo for 13 weeks. The results, stated precisely:
- Total sleep time (the pre-specified primary endpoint) — met. Children slept 57.5 minutes longer on average with PedPRM versus 9.1 minutes with placebo (adjusted mean treatment difference 32.4 minutes; p=0.034).
- Sleep latency — significant. Down 39.6 minutes on average with PedPRM versus 12.5 with placebo (adjusted mean treatment difference 25.3 minutes; p=0.011), without causing earlier wake-up.
- Clinically meaningful response — significant. 68.9% on PedPRM versus 39.3% on placebo (p=0.001), a number needed to treat of 3.4.
- Overall sleep disturbance (Composite Sleep Disturbance Index) — not significant. It "tended to decrease." An earlier version of this article described this as a significant improvement in "sleep continuity." It wasn't, and that mattered enough to correct.
- Safety. PedPRM was generally safe, but somnolence was more commonly reported with PedPRM than placebo — not "minimal adverse effects" without qualification.
The evidence is real. It's also mostly pediatric, prescription-strength, and specific to sleep onset and duration — not a reason to treat autism itself as something a supplement addresses.
It's worth being precise about what these trials measured and who was in them. They enrolled children and adolescents already diagnosed with autism spectrum disorder and a confirmed sleep problem that behavioural approaches hadn't fixed, they used a specific prolonged-release formulation and escalating dose protocol developed for that population, and the outcome was improved sleep — not any change to autism's core features. That distinction matters both scientifically and ethically: autism is a form of neurological difference, not an illness to be corrected, and the trials were never designed to test whether melatonin does anything to autism itself. They tested whether it helps autistic kids who can't sleep, actually sleep.
Why this evidence base matters for adults too — with one important caveat
There is no dedicated randomized trial of melatonin for sleep-onset difficulty in autistic adults. That is an honest gap in the research, and we're not going to paper over it. What autistic adults are left with is the same general-population melatonin evidence everyone else has access to, plus a reasonable expectation — not a demonstrated one — that the same basic mechanism of shifting a delayed or irregular circadian signal is likely to apply.
On dose in adults, the best pooled evidence is a dose-response meta-analysis of 26 randomised, double-blind controlled trials published between 1987 and 2020, contributing 1,689 observations across insomnia patients and healthy volunteers. It found melatonin progressively shortens the time taken to fall asleep and lengthens total sleep time, peaking at 4mg/day — and, separately, that administering it around three hours before the intended bedtime outperformed the 30-minutes-before-bed schedule most people and most product labels assume.6 Two things follow. More is not better past that point, so the common retail practice of selling 5mg and 10mg tablets is not a dose-response argument. And timing may matter as much as amount, which is the part almost no label addresses. On tolerability, a systematic review of 37 randomised trials at doses from 0.15mg to 12mg found adverse events uncommon and mild — daytime sleepiness in 1.7% of participants, headache and dizziness each under 1% — while noting that long-term data is genuinely scarce.7 Our melatonin dose-response article goes through the adult picture in full, and jet lag and shift work covers the timing logic in more detail.
It's also worth knowing that for chronic insomnia in adults generally, the intervention with the strongest evidence isn't a supplement at all. CBT-I outperforms everything on the supplement shelf, and adaptations of it for autistic people are an active area of research. If sleep-onset difficulty is the chronic, years-long kind, that's the lever worth asking a clinician about first.
Where Proco's products fit — and where they don't
Sleep Support (10mg melatonin per serving) and Sleep Formula (2mg melatonin per serving, individually dosed alongside valerian 150mg, chamomile 100mg, GABA 100mg, L-tryptophan 100mg, lemon balm 100mg and passion flower 100mg) are formulated for adults. Neither product is intended for, dosed for, tested in, or marketed to children of any diagnosis or neurotype, autistic or not. The strongest melatonin-autism trial evidence used a specific pediatric prolonged-release prescription formulation, in specific escalating pediatric doses, under clinical supervision, in children who had already tried behavioural approaches. That is a meaningfully different product, dosed and delivered differently, from an adult over-the-counter supplement, and the two should not be treated as interchangeable.
One more thing we'd rather state than bury: Sleep Support's 10mg of melatonin sits well above the range where additional benefit has been demonstrated in adults. That is a fact about our own label, and how to choose between the two products goes through what it means in practice.
If you're a parent or caregiver of an autistic child struggling with sleep, the right next step is a conversation with a pediatrician or your child's care team — not substituting an adult supplement, ours or anyone else's. A pediatrician can weigh dose, formulation, timing, interactions with any other medications, and whether melatonin is appropriate at all for that specific child. For autistic adults evaluating melatonin for their own sleep-onset difficulty, the same general adult evidence, dosing, and precautions that apply to anyone else apply here too.
Bottom line
Sleep-onset and sleep-maintenance difficulty is one of the best-documented co-occurring features of autism, affecting a large share of autistic children and, on a much smaller evidence base, autistic adults too. Melatonin is the supplement with the most rigorous trial support for that specific symptom — including a genuinely strong pediatric prescription-grade trial that's rare in this category, with clearly-stated limits on what it did and didn't move. What none of that evidence supports is treating melatonin, or any supplement, as something that addresses autism itself. It addresses sleep timing. For autistic adults, general adult melatonin evidence applies, with adult-appropriate products and doses kept inside the range the trials actually cover; for autistic children, the right move is a pediatrician's guidance, not an adult supplement aisle.
This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Speak with a healthcare provider before starting any new supplement, especially if you take medication or have an existing health condition. This article does not describe a treatment for autism — autism is not a disease — and the products discussed are formulated for adults; they are not intended for, dosed for, or marketed to children.
References
- Schwichtenberg AJ, Janis A, Lindsay A, Desai H, Sahu A, Kellerman A, Chong PLH, Abel EA, Yatcilla JK. Sleep in Children with Autism Spectrum Disorder: A Narrative Review and Systematic Update. Current Sleep Medicine Reports. pmc.ncbi.nlm.nih.gov/articles/PMC9630805
- Morgan B, Nageye F, Masi G, Cortese S. Sleep in adults with Autism Spectrum Disorder: a systematic review and meta-analysis of subjective and objective studies. Sleep Medicine, 2020;65:113-120. sciencedirect.com
- Prevalence and Early Identification of Autism Spectrum Disorder Among Children Aged 4 and 8 Years — Autism and Developmental Disabilities Monitoring Network, 16 Sites, United States, 2022. MMWR Surveillance Summaries, CDC, 2025;74(2). cdc.gov
- Gringras P, Nir T, Breddy J, Frydman-Marom A, Findling RL. Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 2017;56(11):948-957. pubmed.ncbi.nlm.nih.gov/29096777
- Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Developmental Medicine & Child Neurology, 2011;53(9):783-792. pubmed.ncbi.nlm.nih.gov/21518346
- Cruz-Sanabria F, Bruno S, Crippa A, Frumento P, Scarselli M, Skene DJ, Faraguna U. Optimizing the time and dose of melatonin as a sleep-promoting drug: a systematic review of randomized controlled trials and dose-response meta-analysis. J Pineal Res. 2024. doi:10.1111/jpi.12985
- Besag FMC, Vasey MJ, Lao KSJ, Wong ICK. Adverse events associated with melatonin for the treatment of primary or secondary sleep disorders: a systematic review. CNS Drugs. 2019. doi:10.1007/s40263-019-00680-w
Related reading: Melatonin: The Real Dose-Response Evidence and The Science of Deep Sleep: Separating What Works from What's Marketing.
Want to know what's actually in what you take? Join the list — no spam, just it straight.